Kymera Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
KYMR$136.64-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
For the nine months ended September 30, 2025 and 2024
(In thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net loss | $(224,370) | $(153,106) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 45,451 | 41,213 |
| Lease impairment charge | 3,855 | 4,925 |
| Depreciation and amortization | 6,281 | 5,386 |
| Premiums and discounts on available-for-sale marketable securities | (6,834) | (10,716) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (2,039) | (5,754) |
| Accounts receivable | — | 15,000 |
| Contract asset | 947 | 2,445 |
| Other non-current assets | (4,878) | 2,118 |
| Accounts payable | (483) | 198 |
| Accrued expenses and other current liabilities | (6,275) | (4,842) |
| Deferred revenue | 23,660 | (34,627) |
| Operating lease right-of-use assets | 2,070 | 1,883 |
| Operating lease liabilities | (3,713) | 3,048 |
| Other assets and liabilities | 184 | 112 |
| Net cash used in operating activities | (166,144) | (132,717) |
| Investing activities | ||
| Purchase of property and equipment, net | (1,343) | (11,902) |
| Purchases of investments | (509,465) | (822,804) |
| Maturities of investments | 384,145 | 362,061 |
| Net cash used in investing activities | (126,663) | (472,645) |
| Financing activities | ||
| Issuance of common stock and accompanying pre-funded warrants from January 2024 public offering, net of issuance costs of $14.9 million | — | 301,373 |
| Proceeds from issuance of common stock through At-The Market Sales Agreement, net of issuance costs of $1.2 million | — | 48,740 |
| Issuance of common stock and accompanying pre-funded warrants from August 2024 public offering, net of issuance costs of $12.2 million | — | 246,506 |
| Issuance of common stock and accompanying pre-funded warrants from June 2025 public offering, net of issuance costs of $15.7 million | 272,671 | — |
| Proceeds from stock option exercises | 12,789 | 9,616 |
| Proceeds from employee stock purchase plan | 1,112 | 1,134 |
| Payments on finance leases | (1,078) | (1,283) |
| Net cash provided by financing activities | 285,494 | 606,086 |
| Net increase in cash, cash equivalents and restricted cash | (7,313) | 724 |
| Cash, cash equivalents and restricted cash at beginning of period | 126,050 | 115,777 |
| Cash, cash equivalents and restricted cash at end of period | $118,737 | $116,501 |
| Supplemental disclosure of cash flow activities | ||
| Cash paid for interest | $237 | $144 |
| Supplemental disclosure of noncash investing and financing activities | ||
| Property and equipment purchases included in accounts payable and accrued expenses | $1,028 | $744 |
| Purchase of property and equipment through finance lease | $107 | $1,793 |
The following table provides a reconciliation of the cash, cash equivalents, and restricted cash balances as of each of the periods shown above:
| September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash and cash equivalents | $112,949 | $110,718 |
| Restricted cash | 5,788 | 5,783 |
| Total cash, cash equivalents, and restricted cash | $118,737 | $116,501 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.